125 related articles for article (PubMed ID: 2713222)
21. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
[TBL] [Abstract][Full Text] [Related]
22. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.
Gross AS; Mikus G; Fischer C; Hertrampf R; Gundert-Remy U; Eichelbaum M
Br J Clin Pharmacol; 1989 Nov; 28(5):555-66. PubMed ID: 2511912
[TBL] [Abstract][Full Text] [Related]
23. [Insufficient effect of nortriptyline in a rapid metabolizer of sparteine].
Stage KB; Brøsen K
Ugeskr Laeger; 1993 May; 155(20):1561-3. PubMed ID: 8316990
[TBL] [Abstract][Full Text] [Related]
24. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
Holomán J; Glasa J; Veningerová M; Prachar V; Lukácsová M
Bratisl Lek Listy; 1997 Feb; 98(2):86-90. PubMed ID: 9264814
[TBL] [Abstract][Full Text] [Related]
25. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
Broly F; Vandamme N; Libersa C; Lhermitte M
Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
[TBL] [Abstract][Full Text] [Related]
26. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
[TBL] [Abstract][Full Text] [Related]
27. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
Furukori H
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
[TBL] [Abstract][Full Text] [Related]
28. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
[TBL] [Abstract][Full Text] [Related]
29. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
[TBL] [Abstract][Full Text] [Related]
30. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.
Sindrup SH; Gram LF; Skjold T; Grodum E; Brøsen K; Beck-Nielsen H
Br J Clin Pharmacol; 1990 Nov; 30(5):683-91. PubMed ID: 2271367
[TBL] [Abstract][Full Text] [Related]
31. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
32. Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio.
Lam YW; Chang WH; Jann MW; Chen H
Neuropsychopharmacology; 1992 Aug; 7(1):33-9. PubMed ID: 1524655
[TBL] [Abstract][Full Text] [Related]
33. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
Brøsen K; Davidsen F; Gram LF
Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
[TBL] [Abstract][Full Text] [Related]
34. SPECT studies of D2 occupancy in low-dose haloperidol treatment.
Hirschowitz J; Hitzemann R; Vallabhajosula S
Am J Psychiatry; 1997 May; 154(5):715-6. PubMed ID: 9137141
[No Abstract] [Full Text] [Related]
35. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
[TBL] [Abstract][Full Text] [Related]
36. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
[TBL] [Abstract][Full Text] [Related]
37. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
Hollister LE; Kim DY
Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
[TBL] [Abstract][Full Text] [Related]
38. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
[TBL] [Abstract][Full Text] [Related]
39. Blood levels of haloperidol in schizophrenic patients.
Shvartsburd A; Dekirmenjian H; Smith RC
J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
[TBL] [Abstract][Full Text] [Related]
40. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
Magliozzi JR; Hollister LE; Arnold KV; Earle GM
Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
